To identify the circulating serotype(s) of dengue viruses in Bangladesh, a retrospective molecular identification was performed on stored serum samples of dengue surveillance during the period of 2013-2016. Real time RT-PCR was performed on serum samples collected from the patients with less than 5 days fever for detection of dengue virus nucleic acid. The samples, positive for dengue PCR were further analyzed for serotypes by real time RT-PCR. The overall prevalence of dengue virus infection was varied among 13-42% in study years with a single peak flanked by April to September. Among the four dengue serotypes DEN1 and DEN2 were in the circulation in three metropolitan cities with sequential emergence of DEN1 where DEN2 was persisted constantly during the study period. Persistence of all four serotypes in the neighboring country makes Bangladesh vulnerable for devastating secondary infection by introduction of new serotype(s) other than currently circulating viruses in the country. Thus continuous virological surveillance is crucial for early warning of emergence of new serotype in the circulation and public health preparedness.
Hepatitis B virus infection is a vaccine preventable infection of liver which remains a key public health burden globally. The development of Anti-HBs titre greater than or equal to 10 IU/L is considered as protective immunity and any titre less than 10 IU/L as non-protective following HBV vaccination. There is no comprehensive and authentic data regarding the immune response even 10 years after the integration of the HBV vaccine in to the EPI programme in Bangladesh and specifically, in Brahmonbaria district. The study was also aimed to assess the long term immune response among HBV vaccinated children. Blood sample from 500 vaccinated children were tested for Anti-HBs, and anti-HBc. Sero negative children were given 1 dose of HBV vaccine as a booster. Samples from booster vaccine were taken one month later and tested for anti Hbs titre. Anti HBs titre was found below protective level in about 46.0% (230/500) participants. Sero-protection rate decreased to 72.2% in 5 to 6 years age group which further decreased to 58.3% in 7 to 9 years age group and increased again to 69.5% in 10 to 12 years age group children. On the other hand, the mean anti Hbs titre was 97.72 IU/L initially and then increased with the increasing of age from 165.40 IU/L to 196.67 IU/L. Breakthrough infection of HBV was seen in 1.2% (6/500) participants measuring by anti HBc which indicated protective efficacy of HBV vaccine was about 98.8% (494/500). Sero negative participants were given a booster dose; 93.6% (131/140) participants showed boosting of mean anti HBs titre upto 804.92 IU/L which was below protective level (<10 IU/L) before booster dose. Anti-HBs titre goes below with the increase of age after vaccination. Most of the participants had immunological memory which will boost antibody titre after any exposure, so routine booster dose is not needed. But non-responder to vaccination should screen after primary vaccination because of chance of breakthrough infection.
Background: Pseudomonas aeruginosa is an aerobic, motile, gram negative rod that belongs to the family, Pseudomonadaceae. They are often multidrug resistant due to intrinsic and acquired determinants. Continued emergence of resistance among P. aeruginosa to common antimicrobial drugs has been reported world-wide.Objectives: This study investigated the antimicrobial resistance as well as susceptibility patterns of isolates of P. aeruginosa in clinical specimens.Materials & Methods: One hundred and thirty-eight isolates of Pseudomonas aeruginosa were obtained from 4489 different clinical specimens. Antimicrobial susceptibility pattern of each isolate was carried out by the Kirby- Bauer disk diffusion method as per guidelines of Clinical Laboratory Standard Institute (CLSI).Results: Majority of isolates of P. aeruginosa were obtained from specimens of wound swab 89 (64.5%), pus 18 (13.05%), and urine 17 (13.1%). The isolated pathogens showed high resistance (91% to 96%) to cotrimoxazole and cefuroxime. Resistance rates to cefepime, ceftriaxone, cefotaxime, and gentamicin varied from 47% to 88%. All the isolates were comparatively better susceptible to meropenem, ciprofloxacin, amikacin and imipenem ranges from 76% to 87%.Conclusion: The results confirmed the occurrence of drug resistance of P. aeruginosa to anti-pseudomonal drugs. Imipenem, amikacin, ciprofloxacin and meropenem were found to be the most effective antimicrobial drugs. Therefore, judicious and rational treatment prescription is needed by the physicians to limit the further spread of antimicrobial resistance among the P. aeruginosa.KYAMC Journal Vol. 9, No.-1, April 2018, Page 16-19
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.